Literature DB >> 7564678

Combination superior to zidovudine in Delta trial.

V Choo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7564678     DOI: 10.1016/s0140-6736(95)92725-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  Antiretroviral therapy for patients with HIV disease.

Authors:  M Barry; F Mulcahy; D J Back
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

2.  Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17.

Authors:  R Levin; A M Mhashilkar; T Dorfman; A Bukovsky; C Zani; J Bagley; J Hinkula; M Niedrig; J Albert; B Wahren; H G Göttlinger; W A Marasco
Journal:  Mol Med       Date:  1997-02       Impact factor: 6.354

3.  Quantitative molecular monitoring of HIV-1 RNA during antiretroviral therapy.

Authors:  A Lafeuillade; C Poggi; P Pellegrino; N Profizi
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

Review 4.  Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.

Authors:  M Barry; S Gibbons; D Back; F Mulcahy
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

5.  Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

Authors:  Samantha Abel; Deborah Russell; Richard J Taylor-Worth; Caroline E Ridgway; Gary J Muirhead
Journal:  Br J Clin Pharmacol       Date:  2008-04       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.